このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

PolyNovo 将来の成長

Future 基準チェック /66

PolyNovo利益と収益がそれぞれ年間49.3%と20.5%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に23.4% 49.1%なると予測されています。

主要情報

49.3%

収益成長率

49.1%

EPS成長率

Medical Equipment 収益成長	17.0%
収益成長率	20.5%
将来の株主資本利益率	23.4%
アナリストカバレッジ	Good
最終更新日	18 May 2024

今後の成長に関する最新情報

Recent updates

PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

Jan 08

Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

Sep 22

When Should You Buy PolyNovo Limited (ASX:PNV)?

Jun 26

Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

May 30

Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Apr 18

Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Mar 23

Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Feb 05

Returns At PolyNovo (ASX:PNV) Are On The Way Up

Nov 16

PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

Nov 01

What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

Jul 29

PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital

Jun 15

Estimating The Fair Value Of PolyNovo Limited (ASX:PNV)

May 16

We Think PolyNovo (ASX:PNV) Is Taking Some Risk With Its Debt

Apr 28

There's Been No Shortage Of Growth Recently For PolyNovo's (ASX:PNV) Returns On Capital

Mar 07

Is PolyNovo (ASX:PNV) Weighed On By Its Debt Load?

Dec 13

PolyNovo Limited's (ASX:PNV) CEO Compensation Looks Acceptable To Us And Here's Why

Oct 19

Is PolyNovo (ASX:PNV) Using Debt In A Risky Way?

May 08

News Flash: 7 Analysts Think PolyNovo Limited (ASX:PNV) Earnings Are Under Threat

Feb 27

Earnings Update: PolyNovo Limited (ASX:PNV) Just Reported And Analysts Are Trimming Their Forecasts

Feb 25

Is PolyNovo Limited (ASX:PNV) Potentially Undervalued?

Feb 17

These Analysts Think PolyNovo Limited's (ASX:PNV) Earnings Are Under Threat

Jan 14

Breakeven Is Near for PolyNovo Limited (ASX:PNV)

Dec 28

業績と収益の成長予測

ASX:PNV - アナリストの将来予測と過去の財務データ ( )AUD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
6/30/2026	167	24	8	23	7
6/30/2025	133	13	-4	12	8
6/30/2024	103	4	0	2	8
12/31/2023	83	2	-6	-3	N/A
9/30/2023	75	-2	-7	-5	N/A
6/30/2023	66	-5	-8	-7	N/A
3/31/2023	59	-6	-5	-4	N/A
12/31/2022	53	-7	-2	-2	N/A
9/30/2022	48	-4	-2	-2	N/A
6/30/2022	42	-1	-3	-2	N/A
3/31/2022	38	0	-3	-2	N/A
12/31/2021	35	1	-4	-2	N/A
9/30/2021	32	-2	-4	-1	N/A
6/30/2021	29	-5	-4	0	N/A
3/31/2021	27	-5	-6	0	N/A
12/31/2020	25	-5	-7	0	N/A
9/30/2020	24	-5	-8	0	N/A
6/30/2020	22	-4	-9	0	N/A
3/31/2020	20	-4	-11	-2	N/A
12/31/2019	18	-4	-13	-3	N/A
9/30/2019	16	-3	-11	-3	N/A
6/30/2019	14	-3	-10	-3	N/A
3/31/2019	12	-4	-8	-5	N/A
12/31/2018	9	-5	-7	-6	N/A
9/30/2018	8	-5	-7	-7	N/A
6/30/2018	7	-6	-7	-7	N/A
3/31/2018	6	-6	-7	-7	N/A
12/31/2017	5	-6	-7	-7	N/A
9/30/2017	4	-6	N/A	-6	N/A
6/30/2017	4	-5	N/A	-5	N/A
3/31/2017	4	-4	N/A	-4	N/A
12/31/2016	5	-3	N/A	-3	N/A
9/30/2016	4	-3	N/A	-3	N/A
6/30/2016	3	-3	N/A	-4	N/A
3/31/2016	2	-3	N/A	-4	N/A
12/31/2015	0	-2	N/A	-4	N/A
9/30/2015	0	-2	N/A	-3	N/A
6/30/2015	0	-1	N/A	-3	N/A
3/31/2015	0	-2	N/A	-2	N/A
12/31/2014	0	-3	N/A	-2	N/A
9/30/2014	0	-3	N/A	-2	N/A
6/30/2014	0	-3	N/A	-3	N/A
3/31/2014	0	-2	N/A	-3	N/A
12/31/2013	0	-2	N/A	-3	N/A
9/30/2013	0	-2	N/A	-2	N/A
6/30/2013	0	-1	N/A	-2	N/A

アナリストによる今後の成長予測

収入対貯蓄率: PNVの予測収益成長率 (年間49.3% ) は貯蓄率 ( 2.3% ) を上回っています。

収益対市場: PNVの収益 ( 49.3% ) はAustralian市場 ( 13.8% ) よりも速いペースで成長すると予測されています。

高成長収益: PNVの収益は今後 3 年間で大幅に増加すると予想されています。

収益対市場: PNVの収益 ( 20.5% ) Australian市場 ( 5.4% ) よりも速いペースで成長すると予測されています。

高い収益成長: PNVの収益 ( 20.5% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: PNVの自己資本利益率は、3年後には高くなると予測されています ( 23.4 %)

PolyNovo 将来の成長

Future 基準チェック /66

主要情報

今後の成長に関する最新情報

Price target increased by 9.7% to AU$2.14

Price target increased by 7.4% to AU$1.95

Price target decreased by 9.5% to AU$1.88

Price target decreased by 7.8% to AU$2.07

Consensus EPS estimates fall by 65%, revenue upgraded

Forecast breakeven date pushed back to 2025

Recent updates

PolyNovo Limited's (ASX:PNV) P/S Is On The Mark

Now 21% undervalued

Now 23% undervalued

Now 20% undervalued

Price target increased by 9.7% to AU$2.14

When Should You Buy PolyNovo Limited (ASX:PNV)?

First half 2024 earnings released: EPS: AU$0.004 (vs AU$0.006 loss in 1H 2023)

Why Investors Shouldn't Be Surprised By PolyNovo Limited's (ASX:PNV) P/S

Price target increased by 7.4% to AU$1.95

PolyNovo Limited (ASX:PNV) Shares Could Be 47% Below Their Intrinsic Value Estimate

PolyNovo Limited, Annual General Meeting, Nov 03, 2023

Price target decreased by 9.5% to AU$1.88

Health Check: How Prudently Does PolyNovo (ASX:PNV) Use Debt?

Price target decreased by 7.8% to AU$2.07

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates fall by 65%, revenue upgraded

Forecast breakeven date pushed back to 2025

When Should You Buy PolyNovo Limited (ASX:PNV)?

Are Investors Undervaluing PolyNovo Limited (ASX:PNV) By 29%?

Price target decreased by 11% to AU$2.25

Forecast breakeven date pushed back to 2025

Shareholders Should Be Pleased With PolyNovo Limited's (ASX:PNV) Price

Independent Non-Executive Chairman recently sold AU$9.7m worth of stock

Is It Too Late To Consider Buying PolyNovo Limited (ASX:PNV)?

Now 23% undervalued after recent price drop

Forecast breakeven date moved forward to 2023

First half 2023 earnings released: AU$0.006 loss per share (vs AU$0.002 profit in 1H 2022)

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

PolyNovo Limited Announces Update on SynPath Diabetic Foot Ulcer Trial

Price target increased by 13% to AU$2.36

Consensus EPS estimates upgraded to AU$0.0002 loss

Is PolyNovo Limited (ASX:PNV) Worth AU$2.6 Based On Its Intrinsic Value?

Forecast breakeven date pushed back to 2024

Price target increased to AU$1.98

Price target increased to AU$1.90

Returns At PolyNovo (ASX:PNV) Are On The Way Up

PolyNovo Limited's (ASX:PNV) Intrinsic Value Is Potentially 95% Above Its Share Price

Independent Non-Executive Chairman recently bought AU$202k worth of stock

PolyNovo Limited, Annual General Meeting, Oct 28, 2022

PolyNovo Limited Announces Re-Designation of David McQuillan as Chief Technical and Scientific Officer

Price target increased to AU$1.68

Full year 2022 earnings: EPS misses analyst expectations

Now 21% undervalued

PolyNovo Limited Announces First Patient Enrolled in Clinical Trial of NovoSorb SynPath Treatment for Diabetic Foot Ulcers

PolyNovo Limited Announces CEO Changes

PolyNovo Limited Announces CEO Changes

What Does PolyNovo Limited's (ASX:PNV) Share Price Indicate?

Consensus forecasts updated

Now 21% undervalued

PolyNovo (ASX:PNV) Is Looking To Continue Growing Its Returns On Capital

Independent Non-Executive Chairman recently bought AU$956k worth of stock

Now 23% undervalued

Estimating The Fair Value Of PolyNovo Limited (ASX:PNV)

Independent Non-Executive Chairman recently bought AU$434k worth of stock

We Think PolyNovo (ASX:PNV) Is Taking Some Risk With Its Debt

Price target decreased to AU$1.57

Consensus forecasts updated

There's Been No Shortage Of Growth Recently For PolyNovo's (ASX:PNV) Returns On Capital

Price target decreased to AU$1.70

First half 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Consensus forecasts updated

Price target decreased to AU$2.04

Is PolyNovo (ASX:PNV) Weighed On By Its Debt Load?

PolyNovo Limited's (ASX:PNV) CEO Compensation Looks Acceptable To Us And Here's Why

PolyNovo Limited Announces First Patient Enrolled in Pivotal Trial of the BARDA Funded Burn Study

Full year 2021 earnings released

Price target decreased to AU$2.48

PolyNovo Limited Provides an Update on its Hernia Device

Is PolyNovo (ASX:PNV) Using Debt In A Risky Way?